Skip to main content

1 Result(s)

within Johanna Lister Remove this filter Health Economics Remove this filter

and

  1. Article

    Open Access

    OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

    The cost-effectiveness of onabotulinumtoxinA (BOTOX®) 100 U + best supportive care (BSC) was compared with BSC alone in the management of idiopathic overactive bladder in adult patients who are not adequately man...

    Nick Freemantle, Kristin Khalaf, Clara Loveman… in The European Journal of Health Economics (2016)

    Download PDF (549 KB) View Article